| Date Filed | Type | Description |
| 08/22/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/12/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/26/2023 |
8-K
| Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, A... |
| 05/02/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 04/13/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
SC 13G
| Park West Asset Management LLC reports a 4.9% stake in PLx Pharma Inc. |
| 03/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/14/2023 |
SC 13G/A
| MSD Partners, L.P. reports a 2.4% stake in PLX PHARMA INC. |
| 02/13/2023 |
8-K
| Quarterly results |
| 01/20/2023 |
8-K
| Quarterly results |
| 11/10/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/07/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 09/29/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 09/29/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/12/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/29/2022 |
10-K/A
| Annual Report for the period ended December 31, 2021 [amend] |
| 04/21/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 03/16/2022 |
4
| Giordano Natasha (CEO) has filed a Form 4 on PLx Pharma Inc.|
Txns:
| Bought 4,100 shares
@ $3.6529, valued at
$15k
|
|
| 03/16/2022 |
4
| O'Connor Rita M (CFO) has filed a Form 4 on PLx Pharma Inc.|
Txns:
| Bought 10,000 shares
@ $3.66, valued at
$36.6k
Bought 3,700 shares
@ $3.6546, valued at
$13.5k
|
|
| 03/15/2022 |
8-K
| Investor presentation |
| 03/11/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/11/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/24/2022 |
4
| Valentino Michael J (Executive Chairman) has filed a Form 4 on PLx Pharma Inc.|
Txns:
| Granted 80,000 options to buy
@ $4.99, valued at
$399.2k
|
|
| 02/24/2022 |
4
| O'Connor Rita M (CFO) has filed a Form 4 on PLx Pharma Inc.|
Txns:
| Granted 110,000 options to buy
@ $4.99, valued at
$548.9k
|
|
| 02/24/2022 |
4
| HADDEN JOHN (Director) has filed a Form 4 on PLx Pharma Inc.|
Txns:
| Granted 20,000 options to buy
@ $4.99, valued at
$99.8k
|
|
| 02/24/2022 |
4
| Giordano Natasha (CEO) has filed a Form 4 on PLx Pharma Inc.|
Txns:
| Granted 300,000 options to buy
@ $4.99, valued at
$1.5M
|
|
| 02/24/2022 |
4
| Casale Robert (Director) has filed a Form 4 on PLx Pharma Inc.|
Txns:
| Granted 20,000 options to buy
@ $4.99, valued at
$99.8k
|
|
| 02/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|